This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Younes, H. Articles by Ghobrial, I. M. Search for Related Content PubMed PubMed Citation Articles by Younes, H. Articles by Ghobrial, I. M.

Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma

Authors' Affiliations: ¹ Department of Internal Medicine, Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania and ² Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Irene M. Ghobrial, Dana-Farber Cancer Institute, 44 Binney Street, Mayer 548A, Boston, MA 02115. Phone: 617-632-4198; E-mail: irene_ghobrial{at}dfci.harvard.edu.

Abstract

Multiple myeloma is a plasma cell neoplasm with a median survival of 3 to 5 years. Recent advances have improved patient outlook, but the disease remains incurable. Therefore, continued efforts to develop new therapies that target aberrant signaling pathways are needed. The phosphatidylinositol 3-kinase pathway regulates apoptosis, cell cycle regulation, and tumor proliferation. This pathway is constitutively activated in multiple myeloma and its inhibition induces apoptosis. Advances in understanding the signaling cascades mediating proliferation and survival of multiple myeloma cells have markedly improved the treatment of this disease. In this article, we review the role of the phosphatidylinositol 3-kinase/Akt pathway in the pathogenesis of multiple myeloma and the potential therapeutic implications of targeting this pathway in the treatment of multiple myeloma.

This article has been cited by other articles:

				Z. Zhu, W. Jiang, J. L. Sells, E. S. Neil, J. N. McGinley, and H. J. Thompson Effect of Nonmotorized Wheel Running on Mammary Carcinogenesis: Circulating Biomarkers, Cellular Processes, and Molecular Mechanisms in Rats Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 1920 - 1929. [Abstract] [Full Text] [PDF]

				I. Airoldi, C. Cocco, N. Giuliani, M. Ferrarini, S. Colla, E. Ognio, G. Taverniti, E. Di Carlo, G. Cutrona, V. Perfetti, et al. Constitutive expression of IL-12R{beta}2 on human multiple myeloma cells delineates a novel therapeutic target Blood, August 1, 2008; 112(3): 750 - 759. [Abstract] [Full Text] [PDF]

				W. Jiang, Z. Zhu, and H. J. Thompson Dietary Energy Restriction Modulates the Activity of AMP-Activated Protein Kinase, Akt, and Mammalian Target of Rapamycin in Mammary Carcinomas, Mammary Gland, and Liver Cancer Res., July 1, 2008; 68(13): 5492 - 5499. [Abstract] [Full Text] [PDF]

				J. C. Montero, R. Lopez-Perez, J. F. San Miguel, and A. Pandiella Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity Haematologica, June 1, 2008; 93(6): 851 - 859. [Abstract] [Full Text] [PDF]

				L. H. Wang, X. Y. Yang, X. Zhang, and W. L. Farrar Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPAR{gamma} cross talk with NF-{kappa}B and C/EBP Blood, December 15, 2007; 110(13): 4373 - 4384. [Abstract] [Full Text] [PDF]